Overview
Cell Signaling Technology (CST) provides antibodies and related research products for scientists, especially in cancer research. Its main offering is antibodies that are thoroughly validated for multiple experimental applications, ensuring reliability across experiments. CST’s antibodies are produced by Ph.D.-level scientists who also deliver technical guidance and support to researchers to help achieve dependable results. The company differentiates itself through its strong emphasis on validation, quality control, and hands-on scientific support from its own researchers, operating with a family-owned, research-institute mindset rather than purely as a generic supplier. CST’s goal is to help researchers obtain accurate, reproducible data by supplying validated antibodies and expert methods guidance for use in the lab.
Work here?Claim your company
Simplify's take
What believers are saying
- Quantum-Si partnership on June 10, 2026 extends CST PTM expertise into protein sequencing.
- October 7, 2026 GMP CAR linker launch opens cell-therapy manufacturing and lot-release revenue.
- Leiden and Beverly ISO 13485 certification on July 16, 2026 lowers customer qualification friction.
What critics are saying
- Reagent commoditization from Quantum-Si, Leveragen, and other platform partners compresses differentiation by 2027.
- Customer dependence on research budgets exposes CST if pharma and academic spending freezes in 2027.
- Supply-chain or QA failure at Beverly or Leiden would damage GMP credibility and trigger existential customer churn.
What makes Cell Signaling Technology unique
- ISO 13485 certifications in Beverly and Leiden strengthen CST’s regulated-reagent moat.
- SignalStar multiplex IHC delivers eight-target spatial biology assays in two days.
- GMP-grade CAR linker antibodies bridge preclinical, manufacturing, and QC workflows across CAR-T programs.
Help us improve and share your feedback! Did you find this helpful?